| Symbol | NKTR |
|---|---|
| Name | NEKTAR THERAPEUTICS |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, California, 94158, United States |
| Telephone | +1 415 482-5300 |
| Fax | — |
| — | |
| Website | https://www.nektar.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0000906709 |
| Description | Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. The company has additional operations facilities in Huntsville, Alabama, and Hyderabad, India. Additional info from NASDAQ: |
2026-08-14 17:49
New Form SCHEDULE 13G/A - NEKTAR THERAPEUTICS <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0001011438-26-000548 <b>Size:</b> 11 KB
Read more
2026-08-14 17:19
New Form SCHEDULE 13G/A - NEKTAR THERAPEUTICS <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0000921895-26-002174 <b>Size:</b> 23 KB
Read more
2026-08-11 11:50
Kuehn Law Encourages Investors of Nektar Therapeutics to Contact Law Firm
Read more
2026-07-28 22:00
Nektar Therapeutics to Announce Financial Results for the Second Quarter on Thursday, August 13, 2026, After Close of U.S.-Based Financial Markets
Read more
2026-07-24 22:35
Zalevsky Jonathan 🟢 acquired 16.5K shares (1 derivative) of NEKTAR THERAPEUTICS (NKTR) at $15.15 Transaction Date: Jul 24, 2026 | Filing ID: 316458
Read more
2026-07-24 22:34
ROBIN HOWARD W 🟢 acquired 57.2K shares (1 derivative) of NEKTAR THERAPEUTICS (NKTR) at $15.15 Transaction Date: Jul 24, 2026 | Filing ID: 316457
Read more
2026-07-24 20:15
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Read more
2026-07-02 23:06
Zalevsky Jonathan 🔴 sold 5.7K shares of NEKTAR THERAPEUTICS (NKTR) at $70.00 Transaction Date: Jun 30, 2026 | Filing ID: 295112
Read more
2026-06-26 20:30
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07711418 | A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age … | Phase3 | Moderate-to-Severe Atopic Dermatitis | Recruiting | 2026-08-01 | 2029-01-01 | ClinicalTrials.gov |
| NCT07690371 | A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age … | Phase3 | Moderate-to-Severe Atopic Dermatitis | Recruiting | 2026-06-29 | 2028-12-01 | ClinicalTrials.gov |
| NCT06340360 | A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Sev… | Phase2 | Alopecia Areata | Active_Not_Recruiting | 2024-04-02 | 2026-08-01 | ClinicalTrials.gov |
| NCT05676749 | C-TIL051 in Non-Small Cell Lung Cancer | Phase1 | Metastatic Non Small Cell Lung Cancer | Terminated | 2024-02-29 | 2025-12-30 | ClinicalTrials.gov |
| NCT06136741 | A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adu… | Phase2 | Moderate to Severe Atopic Dermatitis | Active_Not_Recruiting | 2023-11-15 | 2026-12-31 | ClinicalTrials.gov |
| NCT05632809 | REStoring lymphoCytes Using NKTR-255* After chemoradiothErapy in Solid Tumors (… | Phase2 | Lung Cancer | Recruiting | 2023-01-10 | 2027-12-31 | ClinicalTrials.gov |
| NCT05664217 | NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Rela… | Phase2 | Non-Hodgkin Lymphoma | Terminated | 2022-12-23 | 2024-08-16 | ClinicalTrials.gov |
| NCT05359211 | NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed o… | Phase1 | Recurrent Diffuse Large B-Cell Lymphoma | Active_Not_Recruiting | 2022-12-08 | 2026-09-04 | ClinicalTrials.gov |
| NCT05565729 | A Phase I Study of LY3471851 in Healthy Participants | Phase1 | Healthy | Completed | 2022-10-05 | 2023-02-23 | ClinicalTrials.gov |
| NCT05327530 | A Study of the Safety and Efficacy of Various Combinations of Avelumab as Thera… | Phase2 | Locally Advanced or Metastatic Urothelial Carcinoma | Active_Not_Recruiting | 2022-08-17 | 2026-06-25 | ClinicalTrials.gov |
| NCT04969861 | BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or… | Phase2 | Metastatic Head and Neck Cancer | Terminated | 2022-03-09 | 2022-04-22 | ClinicalTrials.gov |
| NCT04998487 | A Single-Dose Study of LY3471851 in Healthy Participants | Phase1 | Healthy | Completed | 2021-08-16 | 2022-07-06 | ClinicalTrials.gov |
| NCT04936841 | Bempegaldesleukin (NKTR-214) With Radiation and Anti-PD-1 Immunotherapy for Hea… | Phase2 | Head and Neck Cancer | Terminated | 2021-08-05 | 2022-10-04 | ClinicalTrials.gov |
| NCT04730349 | A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab i… | Phase1 | Ependymoma | Terminated | 2021-06-03 | 2022-06-22 | ClinicalTrials.gov |
| NCT04677179 | A Study of LY3471851 in Adult Participants With Moderately to Severely Active U… | Phase2 | Colitis, Ulcerative | Terminated | 2021-03-22 | 2022-08-09 | ClinicalTrials.gov |
| NCT04646044 | A Placebo Controlled Trial of Bempegaldesleukin (BEMPEG; NKTR-214) With Standar… | Phase1 | Covid-19 | Completed | 2020-11-13 | 2021-05-18 | ClinicalTrials.gov |
| NCT04616196 | Study of NKTR 255 in Combination With Cetuximab in Solid Tumors | Phase1 | Head and Neck Squamous Cell Carcinoma | Completed | 2020-10-30 | 2023-03-30 | ClinicalTrials.gov |
| NCT04540705 | A Study to Compare Bempegaldesleukin (BEMPEG: NKTR-214) Combined With Nivolumab… | Phase1 | Renal Cell Carcinoma | Completed | 2020-09-11 | 2024-01-18 | ClinicalTrials.gov |
| NCT04433585 | A Study of LY3471851 in Adults With Systemic Lupus Erythematosus (SLE) | Phase2 | Systemic Lupus Erythematosus | Completed | 2020-08-19 | 2023-02-16 | ClinicalTrials.gov |
| NCT04410445 | Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivo… | Phase3 | Melanoma | Terminated | 2020-07-27 | 2022-09-22 | ClinicalTrials.gov |
| NCT04209114 | A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alon… | Phase3 | Bladder Cancer | Completed | 2020-02-05 | 2023-06-07 | ClinicalTrials.gov |
| NCT04052204 | Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in … | Phase1 | Squamous Cell Carcinoma of the Head and Neck (SCCHN) | Terminated | 2019-12-30 | 2020-09-29 | ClinicalTrials.gov |
| NCT04081350 | A Study of LY3471851 in Participants With Eczema | Phase1 | Dermatitis, Atopic | Completed | 2019-12-04 | 2022-06-24 | ClinicalTrials.gov |
| NCT04119557 | A Study of LY3471851 in Participants With Psoriasis | Phase1 | Psoriasis | Completed | 2019-11-26 | 2021-07-21 | ClinicalTrials.gov |
| NCT04133116 | A Study of LY3471851 in Healthy Participants | Phase1 | Healthy | Completed | 2019-10-29 | 2020-03-06 | ClinicalTrials.gov |
| NCT04136756 | NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma | Phase1 | Multiple Myeloma | Completed | 2019-10-07 | 2023-04-24 | ClinicalTrials.gov |
| NCT04955262 | A CD8 Positron Emission Tomography With Computed Tomography (PET/CT) Study Usin… | Phase1 | Metastatic Melanoma | Withdrawn | 2019-08-01 | 2022-01-01 | ClinicalTrials.gov |
| NCT03785925 | A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin … | Phase2 | Urinary Bladder Neoplasm | Completed | 2019-04-29 | 2022-06-30 | ClinicalTrials.gov |
| NCT03745807 | An Investigational Study of NKTR-214 Combined With Nivolumab in Japanese Partic… | Phase1 | Advanced Cancer | Completed | 2019-04-09 | 2019-12-18 | ClinicalTrials.gov |
| NCT03729245 | A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab C… | Phase3 | Renal Cell Carcinoma | Terminated | 2018-12-18 | 2022-10-19 | ClinicalTrials.gov |
| NCT03802227 | A Study Using fMRI Imaging to Evaluate the Effect of NKTR-181 on Brain Activity… | Phase1 | Moderate to Severe Chronic Pain | Terminated | 2018-10-22 | 2020-01-03 | ClinicalTrials.gov |
| NCT03635983 | A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants … | Phase3 | Melanoma | Completed | 2018-09-21 | 2024-03-19 | ClinicalTrials.gov |
| NCT03556007 | A Study of NKTR-358 (LY3471851) in Participants With Systemic Lupus Erythematos… | Phase1 | Systemic Lupus Erythematosus | Completed | 2018-04-18 | 2019-08-29 | ClinicalTrials.gov |
| NCT03548467 | A Study to Evaluate Safety and Efficacy of Multiple Dosing With VB10.NEO and Be… | Phase1 | Locally Advanced or Metastatic Solid Tumours | Completed | 2018-04-04 | 2023-01-30 | ClinicalTrials.gov |
| NCT03435640 | REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients… | Phase1 | Melanoma | Terminated | 2018-03-15 | 2022-05-09 | ClinicalTrials.gov |
| NCT03138889 | Bempegaldesleukin and Pembrolizumab With or Without Chemotherapy in Locally Adv… | Phase1 | Non-Small Cell Lung Cancer | Terminated | 2017-06-09 | 2022-08-24 | ClinicalTrials.gov |
| NCT04380324 | A Study of NKTR-358 (LY3471851) in Healthy Participants | Phase1 | Healthy | Completed | 2017-03-19 | 2019-01-20 | ClinicalTrials.gov |
| NCT02983045 | A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Ni… | Phase1 | Melanoma | Completed | 2016-12-19 | 2022-04-28 | ClinicalTrials.gov |
| NCT02915744 | A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice… | Phase3 | Metastasis | Completed | 2016-11-01 | 2020-07-01 | ClinicalTrials.gov |
| NCT02869295 | A Phase 1/2 Multicenter Dose Escalation and Expansion Study Of NKTR-214 In Subj… | Phase1 | Unspecified Adult Solid Tumor, Protocol Specific | Completed | 2015-12-01 | 2018-10-31 | ClinicalTrials.gov |
| NCT02312622 | Phase 2 Etirinotecan Pegol in Refractory Brain Metastases & Advanced Lung Cance… | Phase2 | Stage IV Non-small Cell Lung Cancer (NSCLC) | Completed | 2015-08-01 | 2019-07-01 | ClinicalTrials.gov |
| NCT02367820 | Long-Term Safety and Tolerability Study of NKTR-181 in Subjects With Chronic Lo… | Phase3 | Low Back Pain | Completed | 2015-04-14 | 2018-01-01 | ClinicalTrials.gov |
| NCT02362672 | Efficacy and Safety Study of NKTR-181 in Opioid-Naive Subjects With Low Back Pa… | Phase3 | Low Back Pain | Completed | 2015-03-11 | 2017-02-01 | ClinicalTrials.gov |
| NCT01976143 | A Study in Cancer Patients to Evaluate the Effect of a Single Dose of NKTR-102 … | Phase1 | Advanced Cancer | Completed | 2014-02-01 | 2016-09-01 | ClinicalTrials.gov |
| NCT01991678 | A Study in Cancer Patients With Hepatic Impairment to Evaluate the Pharmacokine… | Phase1 | Advanced or Metastatic Solid Tumors in Patients With Hepatic Impairment | Completed | 2013-11-01 | 2017-09-01 | ClinicalTrials.gov |
| NCT01876446 | Pegylated Irinotecan NKTR 102 in Treating Patients With Relapsed Small Cell Lun… | Phase2 | Recurrent Small Cell Lung Carcinoma | Completed | 2013-08-29 | 2020-02-24 | ClinicalTrials.gov |
| NCT01799993 | Inhaled Amikacin Solution BAY41-6551 as Adjunctive Therapy in the Treatment of … | Phase3 | Pneumonia, Bacterial | Completed | 2013-04-13 | 2017-04-07 | ClinicalTrials.gov |
| NCT01663012 | Phase II NKTR-102 In Bevacizumab-Resistant High Grade Glioma | Phase2 | Anaplastic Astrocytomas | Completed | 2012-07-01 | 2015-02-01 | ClinicalTrials.gov |
| NCT01619839 | A Phase 2 Study To Assess The Efficacy, Tolerability, And Safety OF NKTR-181 In… | Phase2 | Osteoarthritis of the Knee | Completed | 2012-06-01 | 2013-09-01 | ClinicalTrials.gov |
| NCT01492101 | The BEACON Study (Breast Cancer Outcomes With NKTR-102) | Phase3 | Locally Recurrent Breast Cancer | Completed | 2011-12-01 | 2016-06-01 | ClinicalTrials.gov |
| NCT01457118 | An Extension Study of NKTR-102 in Cancer Patients Previously Enrolled in NKTR-1… | Phase2 | Malignant Solid Tumor | Completed | 2011-10-01 | 2017-11-01 | ClinicalTrials.gov |
| NCT00856375 | NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS… | Phase2 | Colorectal Cancer | Completed | 2008-12-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT00806156 | Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastat… | Phase2 | Tumor | Completed | 2008-10-01 | 2013-01-01 | ClinicalTrials.gov |
| NCT00802945 | Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastat… | Phase2 | Tumor | Completed | 2008-10-01 | 2012-01-01 | ClinicalTrials.gov |
| NCT00598975 | NKTR-102 in Combination With Cetuximab in Patients With Refractory Solid Tumors… | Phase2 | Tumor | Completed | 2008-02-01 | 2011-12-01 | ClinicalTrials.gov |
| NCT00600119 | A Phase 2, Double-Blind, Multiple-Dose Escalation Study to Evaluate NKTR-118 (O… | Phase2 | Opioid Induced Constipation (OIC) | Completed | 2007-12-01 | 2009-04-01 | ClinicalTrials.gov |
| NCT01021436 | Safety, Tolerability and Pharmacokinetics of Aerosolized Amikacin in Intubated … | Phase2 | Pneumonia | Completed | 2007-03-01 | 2007-08-01 | ClinicalTrials.gov |
| NCT00123201 | Study to Evaluate the Efficacy and Safety of Dronabinol Metered Dose Inhaler (M… | Phase2 | Migraine With Aura | Completed | 2005-09-01 | 2007-03-01 | ClinicalTrials.gov |
| NCT01004445 | A Study to Determine the Correct Dose of Amikacin Which is Delivered Directly t… | Phase2 | Pneumonia | Completed | 2005-05-01 | 2006-06-01 | ClinicalTrials.gov |
| NCT00396578 | Aerosolized Antibiotics and Respiratory Tract Infection in Patients on Mechanic… | Phase2 | Ventilator Associated Pneumonia | Completed | 2003-08-01 | 2004-09-01 | ClinicalTrials.gov |
| NCT00370565 | Effect on Glycemic Control of Inhaled Insulin Alone or Added to Dual Oral Thera… | Phase3 | Diabetes Mellitus, Type 2 | Completed | 1999-06-01 | 2000-09-01 | ClinicalTrials.gov |
Total clinical trials: 61
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Placebo | Other | Phase PHASE3 | Moderate-to-Severe Atopic Dermatitis | RECRUITING | NCT07690371 |
| Rezpegaldesleukin | Other | Phase PHASE3 | Moderate-to-Severe Atopic Dermatitis | RECRUITING | NCT07690371 |
| Placebo | Other | Phase PHASE2 | Moderate to Severe Atopic Dermatitis | ACTIVE_NOT_RECRUITING | NCT06136741 |
| Rezpegaldesleukin | Other | Phase PHASE2 | Moderate to Severe Atopic Dermatitis | ACTIVE_NOT_RECRUITING | NCT06136741 |
| Durvalumab | Other | Phase PHASE2 | Lung Cancer | RECRUITING | NCT05632809 |
| NKTR-255 | Other | Phase PHASE2 | Lung Cancer | RECRUITING | NCT05632809 |
| Placebo | Other | Phase PHASE3 | Moderate-to-Severe Atopic Dermatitis | RECRUITING | NCT07711418 |
| Rezpegaldesleukin | Other | Phase PHASE3 | Moderate-to-Severe Atopic Dermatitis | RECRUITING | NCT07711418 |
| Placebo | Other | Phase PHASE2 | Alopecia Areata | ACTIVE_NOT_RECRUITING | NCT06340360 |
| Rezpegaldesleukin | Other | Phase PHASE2 | Alopecia Areata | ACTIVE_NOT_RECRUITING | NCT06340360 |
| Placebo | Other | Phase PHASE3 | Moderate-to-Severe Atopic Dermatitis | RECRUITING | NCT07690371 |
| Rezpegaldesleukin | Other | Phase PHASE3 | Moderate-to-Severe Atopic Dermatitis | RECRUITING | NCT07690371 |
| Durvalumab | Other | Phase PHASE2 | Lung Cancer | RECRUITING | NCT05632809 |
| NKTR-255 | Other | Phase PHASE2 | Lung Cancer | RECRUITING | NCT05632809 |
| Placebo | Other | Phase PHASE2 | Moderate to Severe Atopic Dermatitis | ACTIVE_NOT_RECRUITING | NCT06136741 |
| Rezpegaldesleukin | Other | Phase PHASE2 | Moderate to Severe Atopic Dermatitis | ACTIVE_NOT_RECRUITING | NCT06136741 |
| Placebo | Other | Phase PHASE2 | Moderate to Severe Atopic Dermatitis | ACTIVE_NOT_RECRUITING | NCT06136741 |
| Rezpegaldesleukin | Other | Phase PHASE2 | Moderate to Severe Atopic Dermatitis | ACTIVE_NOT_RECRUITING | NCT06136741 |
| Placebo | Other | Phase PHASE2 | Moderate to Severe Atopic Dermatitis | ACTIVE_NOT_RECRUITING | NCT06136741 |
| Rezpegaldesleukin | Other | Phase PHASE2 | Moderate to Severe Atopic Dermatitis | ACTIVE_NOT_RECRUITING | NCT06136741 |
| Placebo | Other | Phase PHASE2 | Moderate to Severe Atopic Dermatitis | ACTIVE_NOT_RECRUITING | NCT06136741 |
| Rezpegaldesleukin | Other | Phase PHASE2 | Moderate to Severe Atopic Dermatitis | ACTIVE_NOT_RECRUITING | NCT06136741 |
| Placebo | Other | Phase PHASE2 | Moderate to Severe Atopic Dermatitis | ACTIVE_NOT_RECRUITING | NCT06136741 |
| Rezpegaldesleukin | Other | Phase PHASE2 | Moderate to Severe Atopic Dermatitis | ACTIVE_NOT_RECRUITING | NCT06136741 |
| Placebo | Other | Phase PHASE2 | Moderate to Severe Atopic Dermatitis | ACTIVE_NOT_RECRUITING | NCT06136741 |
| Rezpegaldesleukin | Other | Phase PHASE2 | Moderate to Severe Atopic Dermatitis | ACTIVE_NOT_RECRUITING | NCT06136741 |
| NKTR-102 | Other | Phase PHASE1 | Advanced Cancer | COMPLETED | NCT01976143 |
| Nivolumab | Other | Phase PHASE2 | Urinary Bladder Neoplasm | COMPLETED | NCT03785925 |
| Bempegaldesleukin | Other | Phase PHASE2 | Urinary Bladder Neoplasm | COMPLETED | NCT03785925 |
| Pegylated Irinotecan | Other | Phase PHASE2 | Stage IV Non-small Cell Lung Cancer (NSCLC) | COMPLETED | NCT02312622 |
| Placebo | Other | Phase PHASE2 | Pneumonia | COMPLETED | NCT01004445 |
| Amikacin (BAY41-6551) | Other | Phase PHASE2 | Pneumonia | COMPLETED | NCT01004445 |
| Amikacin inhalation solution (BAY41-6551) | Other | Phase PHASE2 | Pneumonia | COMPLETED | NCT01021436 |
| Etirinotecan pegol | Other | Phase PHASE2 | Anaplastic Astrocytomas | COMPLETED | NCT01663012 |
| 50 mg/m2 NKTR 102 | Other | Phase PHASE1 | Advanced or Metastatic Solid Tumors in Patients With Hepatic Impairment | COMPLETED | NCT01991678 |
| 120 mg/m2 NKTR 102 | Other | Phase PHASE1 | Advanced or Metastatic Solid Tumors in Patients With Hepatic Impairment | COMPLETED | NCT01991678 |
| 145 mg/m2 NKTR 102 | Other | Phase PHASE1 | Advanced or Metastatic Solid Tumors in Patients With Hepatic Impairment | COMPLETED | NCT01991678 |
| Aerosolized Placebo | Other | Phase PHASE3 | Pneumonia, Bacterial | COMPLETED | NCT01799993 |
| Amikacin Inhalation Solution (BAY41-6551) | Other | Phase PHASE3 | Pneumonia, Bacterial | COMPLETED | NCT01799993 |
| Pharmacological Study | Other | Phase PHASE2 | Recurrent Small Cell Lung Carcinoma | COMPLETED | NCT01876446 |
| Pegylated Irinotecan | Other | Phase PHASE2 | Recurrent Small Cell Lung Carcinoma | COMPLETED | NCT01876446 |
| Laboratory Biomarker Analysis | Other | Phase PHASE2 | Recurrent Small Cell Lung Carcinoma | COMPLETED | NCT01876446 |
| Placebo to match NKTR-181 BID tablets | Other | Phase PHASE3 | Low Back Pain | COMPLETED | NCT02362672 |
| NKTR-181 BID tablets | Other | Phase PHASE3 | Low Back Pain | COMPLETED | NCT02362672 |
| Treatment of Physician's Choice (TPC) | Drug | Phase PHASE3 | Locally Recurrent Breast Cancer | COMPLETED | NCT01492101 |
| NKTR-102 | Other | Phase PHASE3 | Locally Recurrent Breast Cancer | COMPLETED | NCT01492101 |
| NKTR-181 BID tablets | Other | Phase PHASE3 | Low Back Pain | COMPLETED | NCT02367820 |
| ⁸⁹Zr-Df-IAB22M2C | Other | Phase PHASE1 | Metastatic Melanoma | WITHDRAWN | NCT04955262 |
| Nivolumab | Other | Phase PHASE1 | Metastatic Melanoma | WITHDRAWN | NCT04955262 |
| Bempegaldesleukin (NKTR-214) | Other | Phase PHASE1 | Metastatic Melanoma | WITHDRAWN | NCT04955262 |
| Oxycodone IR | Other | Phase PHASE1 | Moderate to Severe Chronic Pain | TERMINATED | NCT03802227 |
| NKTR-181 | Other | Phase PHASE1 | Moderate to Severe Chronic Pain | TERMINATED | NCT03802227 |
| NKTR-102 50 mg/m2 | Other | Phase PHASE2 | Malignant Solid Tumor | COMPLETED | NCT01457118 |
| NKTR-102 95 mg/m2 | Other | Phase PHASE2 | Malignant Solid Tumor | COMPLETED | NCT01457118 |
| NKTR-102 120 mg/m2 | Other | Phase PHASE2 | Malignant Solid Tumor | COMPLETED | NCT01457118 |
| NKTR-102 145 mg/m2 | Other | Phase PHASE2 | Malignant Solid Tumor | COMPLETED | NCT01457118 |
| NKTR-214 | Other | Phase PHASE1 | Unspecified Adult Solid Tumor, Protocol Specific | COMPLETED | NCT02869295 |
| Placebo | Other | Phase PHASE2 | Osteoarthritis of the Knee | COMPLETED | NCT01619839 |
| NKTR-181 | Other | Phase PHASE2 | Osteoarthritis of the Knee | COMPLETED | NCT01619839 |
| Nivolumab | Other | Phase PHASE1 | Advanced Cancer | COMPLETED | NCT03745807 |
| NKTR-214 | Other | Phase PHASE1 | Advanced Cancer | COMPLETED | NCT03745807 |
| enzalutamide | Other | Phase PHASE1 | Squamous Cell Carcinoma of the Head and Neck (SCCHN) | TERMINATED | NCT04052204 |
| talazoparib | Other | Phase PHASE1 | Squamous Cell Carcinoma of the Head and Neck (SCCHN) | TERMINATED | NCT04052204 |
| Bempegaldesleukin | Other | Phase PHASE1 | Squamous Cell Carcinoma of the Head and Neck (SCCHN) | TERMINATED | NCT04052204 |
| avelumab | Other | Phase PHASE1 | Squamous Cell Carcinoma of the Head and Neck (SCCHN) | TERMINATED | NCT04052204 |
| Pembrolizumab | Other | Phase PHASE2 | Metastatic Head and Neck Cancer | TERMINATED | NCT04969861 |
| Bempegaldesleukin | Other | Phase PHASE2 | Metastatic Head and Neck Cancer | TERMINATED | NCT04969861 |
| nivolumab | Other | Phase PHASE1 | Melanoma | TERMINATED | NCT03435640 |
| bempegaldesleukin | Other | Phase PHASE1 | Melanoma | TERMINATED | NCT03435640 |
| NKTR-262 | Other | Phase PHASE1 | Melanoma | TERMINATED | NCT03435640 |
| Atezolizumab | Other | Phase PHASE1 | Non-Small Cell Lung Cancer | TERMINATED | NCT03138889 |
| Pemetrexed | Other | Phase PHASE1 | Non-Small Cell Lung Cancer | TERMINATED | NCT03138889 |
| Paclitaxel | Other | Phase PHASE1 | Non-Small Cell Lung Cancer | TERMINATED | NCT03138889 |
| Nab paclitaxel | Other | Phase PHASE1 | Non-Small Cell Lung Cancer | TERMINATED | NCT03138889 |
| Carboplatin | Other | Phase PHASE1 | Non-Small Cell Lung Cancer | TERMINATED | NCT03138889 |
| Cisplatin | Other | Phase PHASE1 | Non-Small Cell Lung Cancer | TERMINATED | NCT03138889 |
| Pembrolizumab | Other | Phase PHASE1 | Non-Small Cell Lung Cancer | TERMINATED | NCT03138889 |
| NKTR-214 | Other | Phase PHASE1 | Non-Small Cell Lung Cancer | TERMINATED | NCT03138889 |
| Dose Expansion Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab | Other | Phase PHASE1 | Melanoma | COMPLETED | NCT02983045 |
| Schedule Finding Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab | Other | Phase PHASE1 | Melanoma | COMPLETED | NCT02983045 |
| Dose Expansion Doublet: Combination of NKTR-214 + nivolumab | Other | Phase PHASE1 | Melanoma | COMPLETED | NCT02983045 |
| Dose Escalation Doublet: Combination of NKTR-214 + nivolumab | Other | Phase PHASE1 | Melanoma | COMPLETED | NCT02983045 |
| NKTR-214 | Other | Phase PHASE1 | Ependymoma | TERMINATED | NCT04730349 |
| Nivolumab | Other | Phase PHASE1 | Ependymoma | TERMINATED | NCT04730349 |
| cabozantinib | Other | Phase PHASE3 | Renal Cell Carcinoma | TERMINATED | NCT03729245 |
| nivolumab | Other | Phase PHASE3 | Renal Cell Carcinoma | TERMINATED | NCT03729245 |
| sunitinib | Other | Phase PHASE3 | Renal Cell Carcinoma | TERMINATED | NCT03729245 |
| bempegaldesleukin | Other | Phase PHASE3 | Renal Cell Carcinoma | TERMINATED | NCT03729245 |
| Nab-paclitaxel | Other | Phase PHASE3 | Metastasis | COMPLETED | NCT02915744 |
| Docetaxel | Other | Phase PHASE3 | Metastasis | COMPLETED | NCT02915744 |
| Paclitaxel | Other | Phase PHASE3 | Metastasis | COMPLETED | NCT02915744 |
| Gemcitabine | Other | Phase PHASE3 | Metastasis | COMPLETED | NCT02915744 |
| Vinorelbine | Other | Phase PHASE3 | Metastasis | COMPLETED | NCT02915744 |
| Ixabepilone | Other | Phase PHASE3 | Metastasis | COMPLETED | NCT02915744 |
| Eribulin | Other | Phase PHASE3 | Metastasis | COMPLETED | NCT02915744 |
| NKTR-102 | Other | Phase PHASE3 | Metastasis | COMPLETED | NCT02915744 |
| Nivolumab | Other | Phase PHASE3 | Melanoma | TERMINATED | NCT04410445 |
| Bempegaldesleukin | Other | Phase PHASE3 | Melanoma | TERMINATED | NCT04410445 |
| Bempegaldesleukin | Other | Phase PHASE1 | Locally Advanced or Metastatic Solid Tumours | COMPLETED | NCT03548467 |
| VB10.NEO | Other | Phase PHASE1 | Locally Advanced or Metastatic Solid Tumours | COMPLETED | NCT03548467 |
| Daratumumab | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT04136756 |
| Rituximab | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT04136756 |
| NKTR-255 Q21 | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT04136756 |
| NKTR-255 | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT04136756 |
| Placebo | Other | Phase PHASE2 | Colitis, Ulcerative | TERMINATED | NCT04677179 |
| LY3471851 | Other | Phase PHASE2 | Colitis, Ulcerative | TERMINATED | NCT04677179 |
| Levocetirizine | Other | Phase PHASE1 | Healthy | COMPLETED | NCT05565729 |
| Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT05565729 |
| LY3471851 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT05565729 |
| LY3471851 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT04998487 |
| Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT04380324 |
| LY3471851 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT04380324 |
| Placebo | Other | Phase PHASE1 | Healthy | COMPLETED | NCT04133116 |
| LY3471851 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT04133116 |
| Placebo | Other | Phase PHASE1 | Systemic Lupus Erythematosus | COMPLETED | NCT03556007 |
| LY3471851 | Other | Phase PHASE1 | Systemic Lupus Erythematosus | COMPLETED | NCT03556007 |
| LY3471851 | Other | Phase PHASE1 | Psoriasis | COMPLETED | NCT04119557 |
| Placebo | Other | Phase PHASE1 | Psoriasis | COMPLETED | NCT04119557 |
| Placebo | Other | Phase PHASE1 | Dermatitis, Atopic | COMPLETED | NCT04081350 |
| LY3471851 | Other | Phase PHASE1 | Dermatitis, Atopic | COMPLETED | NCT04081350 |
| Cabozantinib | Other | Phase PHASE1 | Renal Cell Carcinoma | COMPLETED | NCT04540705 |
| Axitinib | Other | Phase PHASE1 | Renal Cell Carcinoma | COMPLETED | NCT04540705 |
| Nivolumab | Other | Phase PHASE1 | Renal Cell Carcinoma | COMPLETED | NCT04540705 |
| Placebo | Other | Phase PHASE1 | Covid-19 | COMPLETED | NCT04646044 |
| Standard of Care | Other | Phase PHASE1 | Covid-19 | COMPLETED | NCT04646044 |
| Bempegaldesleukin | Other | Phase PHASE1 | Covid-19 | COMPLETED | NCT04646044 |
| Palliative Radiation | Other | Phase PHASE2 | Head and Neck Cancer | TERMINATED | NCT04936841 |
| anti-PD-1 therapy | Drug | Phase PHASE2 | Head and Neck Cancer | TERMINATED | NCT04936841 |
| NKTR-214 | Other | Phase PHASE2 | Head and Neck Cancer | TERMINATED | NCT04936841 |
| Placebo | Other | Phase PHASE2 | Systemic Lupus Erythematosus | COMPLETED | NCT04433585 |
| LY3471851 | Other | Phase PHASE2 | Systemic Lupus Erythematosus | COMPLETED | NCT04433585 |
| Bempegaldesleukin | Other | Phase PHASE3 | Bladder Cancer | COMPLETED | NCT04209114 |
| Radical cystectomy (RC) | Other | Phase PHASE3 | Bladder Cancer | COMPLETED | NCT04209114 |
| Nivolumab | Other | Phase PHASE3 | Bladder Cancer | COMPLETED | NCT04209114 |
| Placebo Comparator | Other | Phase PHASE2 | Non-Hodgkin Lymphoma | TERMINATED | NCT05664217 |
| NKTR-255 at 3.0/6.0 μg/kg | Other | Phase PHASE2 | Non-Hodgkin Lymphoma | TERMINATED | NCT05664217 |
| NKTR-255 at 3.0 μg/kg | Other | Phase PHASE2 | Non-Hodgkin Lymphoma | TERMINATED | NCT05664217 |
| NKTR-255 at 1.5 µg/kg | Other | Phase PHASE2 | Non-Hodgkin Lymphoma | TERMINATED | NCT05664217 |
| Nivolumab | Other | Phase PHASE3 | Melanoma | COMPLETED | NCT03635983 |
| NKTR-214 | Other | Phase PHASE3 | Melanoma | COMPLETED | NCT03635983 |
| Cetuximab | Other | Phase PHASE1 | Head and Neck Squamous Cell Carcinoma | COMPLETED | NCT04616196 |
| NKTR-255 | Other | Phase PHASE1 | Head and Neck Squamous Cell Carcinoma | COMPLETED | NCT04616196 |
| C-TIL051 | Other | Phase PHASE1 | Metastatic Non Small Cell Lung Cancer | TERMINATED | NCT05676749 |
| NKTR-255 | Other | Phase PHASE2 | Locally Advanced or Metastatic Urothelial Carcinoma | ACTIVE_NOT_RECRUITING | NCT05327530 |
| M6223 | Other | Phase PHASE2 | Locally Advanced or Metastatic Urothelial Carcinoma | ACTIVE_NOT_RECRUITING | NCT05327530 |
| Sacituzumab Govitecan | Other | Phase PHASE2 | Locally Advanced or Metastatic Urothelial Carcinoma | ACTIVE_NOT_RECRUITING | NCT05327530 |
| Avelumab | Other | Phase PHASE2 | Locally Advanced or Metastatic Urothelial Carcinoma | ACTIVE_NOT_RECRUITING | NCT05327530 |
| Durvalumab | Other | Phase PHASE2 | Lung Cancer | RECRUITING | NCT05632809 |
| NKTR-255 | Other | Phase PHASE2 | Lung Cancer | RECRUITING | NCT05632809 |
| Biopsy | Other | Phase PHASE1 | Recurrent Diffuse Large B-Cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT05359211 |
| Biospecimen Collection | Other | Phase PHASE1 | Recurrent Diffuse Large B-Cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT05359211 |
| Positron Emission Tomography | Other | Phase PHASE1 | Recurrent Diffuse Large B-Cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT05359211 |
| Computed Tomography | Other | Phase PHASE1 | Recurrent Diffuse Large B-Cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT05359211 |
| Lumbar Puncture | Other | Phase PHASE1 | Recurrent Diffuse Large B-Cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT05359211 |
| Bone Marrow Aspiration | Other | Phase PHASE1 | Recurrent Diffuse Large B-Cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT05359211 |
| Bone Marrow Biopsy | Other | Phase PHASE1 | Recurrent Diffuse Large B-Cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT05359211 |
| Multigated Acquisition Scan | Other | Phase PHASE1 | Recurrent Diffuse Large B-Cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT05359211 |
| Echocardiography | Other | Phase PHASE1 | Recurrent Diffuse Large B-Cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT05359211 |
| X-Ray Imaging | Other | Phase PHASE1 | Recurrent Diffuse Large B-Cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT05359211 |
| Polymer-conjugated IL-15 Receptor Agonist NKTR-255 | Other | Phase PHASE1 | Recurrent Diffuse Large B-Cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT05359211 |
| Lisocabtagene Maraleucel | Other | Phase PHASE1 | Recurrent Diffuse Large B-Cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT05359211 |
| Fludarabine | Other | Phase PHASE1 | Recurrent Diffuse Large B-Cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT05359211 |
| Cyclophosphamide | Other | Phase PHASE1 | Recurrent Diffuse Large B-Cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT05359211 |
| Placebo | Other | Phase PHASE2 | Alopecia Areata | ACTIVE_NOT_RECRUITING | NCT06340360 |
| Rezpegaldesleukin | Other | Phase PHASE2 | Alopecia Areata | ACTIVE_NOT_RECRUITING | NCT06340360 |
| Placebo | Other | Phase PHASE2 | Moderate to Severe Atopic Dermatitis | ACTIVE_NOT_RECRUITING | NCT06136741 |
| Rezpegaldesleukin | Other | Phase PHASE2 | Moderate to Severe Atopic Dermatitis | ACTIVE_NOT_RECRUITING | NCT06136741 |
| NKTR-255 | Other | Phase PHASE2 | Locally Advanced or Metastatic Urothelial Carcinoma | ACTIVE_NOT_RECRUITING | NCT05327530 |
| M6223 | Other | Phase PHASE2 | Locally Advanced or Metastatic Urothelial Carcinoma | ACTIVE_NOT_RECRUITING | NCT05327530 |
| Sacituzumab Govitecan | Other | Phase PHASE2 | Locally Advanced or Metastatic Urothelial Carcinoma | ACTIVE_NOT_RECRUITING | NCT05327530 |
| Avelumab | Other | Phase PHASE2 | Locally Advanced or Metastatic Urothelial Carcinoma | ACTIVE_NOT_RECRUITING | NCT05327530 |
| NKTR-255 | Other | Phase PHASE2 | Locally Advanced or Metastatic Urothelial Carcinoma | ACTIVE_NOT_RECRUITING | NCT05327530 |
| M6223 | Other | Phase PHASE2 | Locally Advanced or Metastatic Urothelial Carcinoma | ACTIVE_NOT_RECRUITING | NCT05327530 |
| Sacituzumab Govitecan | Other | Phase PHASE2 | Locally Advanced or Metastatic Urothelial Carcinoma | ACTIVE_NOT_RECRUITING | NCT05327530 |
| Avelumab | Other | Phase PHASE2 | Locally Advanced or Metastatic Urothelial Carcinoma | ACTIVE_NOT_RECRUITING | NCT05327530 |
| NKTR-255 | Other | Phase PHASE2 | Locally Advanced or Metastatic Urothelial Carcinoma | ACTIVE_NOT_RECRUITING | NCT05327530 |
| M6223 | Other | Phase PHASE2 | Locally Advanced or Metastatic Urothelial Carcinoma | ACTIVE_NOT_RECRUITING | NCT05327530 |
| Sacituzumab Govitecan | Other | Phase PHASE2 | Locally Advanced or Metastatic Urothelial Carcinoma | ACTIVE_NOT_RECRUITING | NCT05327530 |
| Avelumab | Other | Phase PHASE2 | Locally Advanced or Metastatic Urothelial Carcinoma | ACTIVE_NOT_RECRUITING | NCT05327530 |
| NKTR-255 | Other | Phase PHASE2 | Locally Advanced or Metastatic Urothelial Carcinoma | ACTIVE_NOT_RECRUITING | NCT05327530 |
| M6223 | Other | Phase PHASE2 | Locally Advanced or Metastatic Urothelial Carcinoma | ACTIVE_NOT_RECRUITING | NCT05327530 |
| Sacituzumab Govitecan | Other | Phase PHASE2 | Locally Advanced or Metastatic Urothelial Carcinoma | ACTIVE_NOT_RECRUITING | NCT05327530 |
| Avelumab | Other | Phase PHASE2 | Locally Advanced or Metastatic Urothelial Carcinoma | ACTIVE_NOT_RECRUITING | NCT05327530 |
| NKTR-255 | Other | Phase PHASE2 | Locally Advanced or Metastatic Urothelial Carcinoma | ACTIVE_NOT_RECRUITING | NCT05327530 |
| M6223 | Other | Phase PHASE2 | Locally Advanced or Metastatic Urothelial Carcinoma | ACTIVE_NOT_RECRUITING | NCT05327530 |
| Sacituzumab Govitecan | Other | Phase PHASE2 | Locally Advanced or Metastatic Urothelial Carcinoma | ACTIVE_NOT_RECRUITING | NCT05327530 |
| Avelumab | Other | Phase PHASE2 | Locally Advanced or Metastatic Urothelial Carcinoma | ACTIVE_NOT_RECRUITING | NCT05327530 |
| NKTR-255 | Other | Phase PHASE2 | Locally Advanced or Metastatic Urothelial Carcinoma | ACTIVE_NOT_RECRUITING | NCT05327530 |
| M6223 | Other | Phase PHASE2 | Locally Advanced or Metastatic Urothelial Carcinoma | ACTIVE_NOT_RECRUITING | NCT05327530 |
| Sacituzumab Govitecan | Other | Phase PHASE2 | Locally Advanced or Metastatic Urothelial Carcinoma | ACTIVE_NOT_RECRUITING | NCT05327530 |
| Avelumab | Other | Phase PHASE2 | Locally Advanced or Metastatic Urothelial Carcinoma | ACTIVE_NOT_RECRUITING | NCT05327530 |
| NKTR-255 | Other | Phase PHASE2 | Locally Advanced or Metastatic Urothelial Carcinoma | ACTIVE_NOT_RECRUITING | NCT05327530 |
| M6223 | Other | Phase PHASE2 | Locally Advanced or Metastatic Urothelial Carcinoma | ACTIVE_NOT_RECRUITING | NCT05327530 |
| Sacituzumab Govitecan | Other | Phase PHASE2 | Locally Advanced or Metastatic Urothelial Carcinoma | ACTIVE_NOT_RECRUITING | NCT05327530 |
| Avelumab | Other | Phase PHASE2 | Locally Advanced or Metastatic Urothelial Carcinoma | ACTIVE_NOT_RECRUITING | NCT05327530 |
| NKTR-255 | Other | Phase PHASE2 | Locally Advanced or Metastatic Urothelial Carcinoma | ACTIVE_NOT_RECRUITING | NCT05327530 |
| M6223 | Other | Phase PHASE2 | Locally Advanced or Metastatic Urothelial Carcinoma | ACTIVE_NOT_RECRUITING | NCT05327530 |
| Sacituzumab Govitecan | Other | Phase PHASE2 | Locally Advanced or Metastatic Urothelial Carcinoma | ACTIVE_NOT_RECRUITING | NCT05327530 |
| Avelumab | Other | Phase PHASE2 | Locally Advanced or Metastatic Urothelial Carcinoma | ACTIVE_NOT_RECRUITING | NCT05327530 |
| NKTR-255 | Other | Phase PHASE2 | Locally Advanced or Metastatic Urothelial Carcinoma | ACTIVE_NOT_RECRUITING | NCT05327530 |
| M6223 | Other | Phase PHASE2 | Locally Advanced or Metastatic Urothelial Carcinoma | ACTIVE_NOT_RECRUITING | NCT05327530 |
| Sacituzumab Govitecan | Other | Phase PHASE2 | Locally Advanced or Metastatic Urothelial Carcinoma | ACTIVE_NOT_RECRUITING | NCT05327530 |
| Avelumab | Other | Phase PHASE2 | Locally Advanced or Metastatic Urothelial Carcinoma | ACTIVE_NOT_RECRUITING | NCT05327530 |
| NKTR-255 | Other | Phase PHASE2 | Locally Advanced or Metastatic Urothelial Carcinoma | ACTIVE_NOT_RECRUITING | NCT05327530 |
| M6223 | Other | Phase PHASE2 | Locally Advanced or Metastatic Urothelial Carcinoma | ACTIVE_NOT_RECRUITING | NCT05327530 |
| Sacituzumab Govitecan | Other | Phase PHASE2 | Locally Advanced or Metastatic Urothelial Carcinoma | ACTIVE_NOT_RECRUITING | NCT05327530 |
| Avelumab | Other | Phase PHASE2 | Locally Advanced or Metastatic Urothelial Carcinoma | ACTIVE_NOT_RECRUITING | NCT05327530 |
| NKTR-255 | Other | Phase PHASE2 | Locally Advanced or Metastatic Urothelial Carcinoma | ACTIVE_NOT_RECRUITING | NCT05327530 |
| M6223 | Other | Phase PHASE2 | Locally Advanced or Metastatic Urothelial Carcinoma | ACTIVE_NOT_RECRUITING | NCT05327530 |
| Sacituzumab Govitecan | Other | Phase PHASE2 | Locally Advanced or Metastatic Urothelial Carcinoma | ACTIVE_NOT_RECRUITING | NCT05327530 |
| Avelumab | Other | Phase PHASE2 | Locally Advanced or Metastatic Urothelial Carcinoma | ACTIVE_NOT_RECRUITING | NCT05327530 |
| NKTR-255 | Other | Phase PHASE2 | Locally Advanced or Metastatic Urothelial Carcinoma | ACTIVE_NOT_RECRUITING | NCT05327530 |
| M6223 | Other | Phase PHASE2 | Locally Advanced or Metastatic Urothelial Carcinoma | ACTIVE_NOT_RECRUITING | NCT05327530 |
| Sacituzumab Govitecan | Other | Phase PHASE2 | Locally Advanced or Metastatic Urothelial Carcinoma | ACTIVE_NOT_RECRUITING | NCT05327530 |
| Avelumab | Other | Phase PHASE2 | Locally Advanced or Metastatic Urothelial Carcinoma | ACTIVE_NOT_RECRUITING | NCT05327530 |
| NKTR-255 | Other | Phase PHASE2 | Locally Advanced or Metastatic Urothelial Carcinoma | ACTIVE_NOT_RECRUITING | NCT05327530 |
| M6223 | Other | Phase PHASE2 | Locally Advanced or Metastatic Urothelial Carcinoma | ACTIVE_NOT_RECRUITING | NCT05327530 |
| Sacituzumab Govitecan | Other | Phase PHASE2 | Locally Advanced or Metastatic Urothelial Carcinoma | ACTIVE_NOT_RECRUITING | NCT05327530 |
| Avelumab | Other | Phase PHASE2 | Locally Advanced or Metastatic Urothelial Carcinoma | ACTIVE_NOT_RECRUITING | NCT05327530 |
| NKTR-255 | Other | Phase PHASE2 | Locally Advanced or Metastatic Urothelial Carcinoma | ACTIVE_NOT_RECRUITING | NCT05327530 |
| M6223 | Other | Phase PHASE2 | Locally Advanced or Metastatic Urothelial Carcinoma | ACTIVE_NOT_RECRUITING | NCT05327530 |
| Sacituzumab Govitecan | Other | Phase PHASE2 | Locally Advanced or Metastatic Urothelial Carcinoma | ACTIVE_NOT_RECRUITING | NCT05327530 |
| Avelumab | Other | Phase PHASE2 | Locally Advanced or Metastatic Urothelial Carcinoma | ACTIVE_NOT_RECRUITING | NCT05327530 |
| Rezpegaldesleukin | DRUG | Phase PHASE2 | Alopecia Areata | ACTIVE_NOT_RECRUITING | NCT06340360 |
| C-TIL051 | BIOLOGICAL | Phase PHASE1 | Metastatic Non Small Cell Lung Cancer | TERMINATED | NCT05676749 |
| Placebo Comparator | OTHER | Phase PHASE2 | Non-Hodgkin Lymphoma | TERMINATED | NCT05664217 |
| NKTR-255 at 3.0/6.0 μg/kg | DRUG | Phase PHASE2 | Non-Hodgkin Lymphoma | TERMINATED | NCT05664217 |
| NKTR-255 at 3.0 μg/kg | DRUG | Phase PHASE2 | Non-Hodgkin Lymphoma | TERMINATED | NCT05664217 |
| NKTR-255 at 1.5 µg/kg | DRUG | Phase PHASE2 | Non-Hodgkin Lymphoma | TERMINATED | NCT05664217 |
| Durvalumab | DRUG | Phase PHASE2 | Lung Cancer | RECRUITING | NCT05632809 |
| Levocetirizine | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT05565729 |
| Biopsy | PROCEDURE | Phase PHASE1 | Recurrent Diffuse Large B-Cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT05359211 |
| Biospecimen Collection | PROCEDURE | Phase PHASE1 | Recurrent Diffuse Large B-Cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT05359211 |
| Positron Emission Tomography | PROCEDURE | Phase PHASE1 | Recurrent Diffuse Large B-Cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT05359211 |
| Computed Tomography | PROCEDURE | Phase PHASE1 | Recurrent Diffuse Large B-Cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT05359211 |
| Lumbar Puncture | PROCEDURE | Phase PHASE1 | Recurrent Diffuse Large B-Cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT05359211 |
| Bone Marrow Aspiration | PROCEDURE | Phase PHASE1 | Recurrent Diffuse Large B-Cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT05359211 |
| Bone Marrow Biopsy | PROCEDURE | Phase PHASE1 | Recurrent Diffuse Large B-Cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT05359211 |
| Multigated Acquisition Scan | PROCEDURE | Phase PHASE1 | Recurrent Diffuse Large B-Cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT05359211 |
| Echocardiography | PROCEDURE | Phase PHASE1 | Recurrent Diffuse Large B-Cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT05359211 |
| X-Ray Imaging | PROCEDURE | Phase PHASE1 | Recurrent Diffuse Large B-Cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT05359211 |
| Polymer-conjugated IL-15 Receptor Agonist NKTR-255 | DRUG | Phase PHASE1 | Recurrent Diffuse Large B-Cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT05359211 |
| Lisocabtagene Maraleucel | BIOLOGICAL | Phase PHASE1 | Recurrent Diffuse Large B-Cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT05359211 |
| Fludarabine | DRUG | Phase PHASE1 | Recurrent Diffuse Large B-Cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT05359211 |
| Cyclophosphamide | DRUG | Phase PHASE1 | Recurrent Diffuse Large B-Cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT05359211 |
| M6223 | DRUG | Phase PHASE2 | Locally Advanced or Metastatic Urothelial Carcinoma | ACTIVE_NOT_RECRUITING | NCT05327530 |
| Sacituzumab Govitecan | DRUG | Phase PHASE2 | Locally Advanced or Metastatic Urothelial Carcinoma | ACTIVE_NOT_RECRUITING | NCT05327530 |
| Avelumab | DRUG | Phase PHASE2 | Locally Advanced or Metastatic Urothelial Carcinoma | ACTIVE_NOT_RECRUITING | NCT05327530 |
| ⁸⁹Zr-Df-IAB22M2C | DRUG | Phase PHASE1 | Metastatic Melanoma | WITHDRAWN | NCT04955262 |
| Bempegaldesleukin (NKTR-214) | BIOLOGICAL | Phase PHASE1 | Metastatic Melanoma | WITHDRAWN | NCT04955262 |
| Palliative Radiation | RADIATION | Phase PHASE2 | Head and Neck Cancer | TERMINATED | NCT04936841 |
| anti-PD-1 therapy | DRUG | Phase PHASE2 | Head and Neck Cancer | TERMINATED | NCT04936841 |
| Standard of Care | DRUG | Phase PHASE1 | Covid-19 | COMPLETED | NCT04646044 |
| Cabozantinib | DRUG | Phase PHASE1 | Renal Cell Carcinoma | COMPLETED | NCT04540705 |
| Axitinib | DRUG | Phase PHASE1 | Renal Cell Carcinoma | COMPLETED | NCT04540705 |
| Radical cystectomy (RC) | PROCEDURE | Phase PHASE3 | Bladder Cancer | COMPLETED | NCT04209114 |
| Daratumumab | DRUG | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT04136756 |
| Rituximab | DRUG | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT04136756 |
| NKTR-255 Q21 | DRUG | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT04136756 |
| NKTR-255 | DRUG | Phase PHASE2 | Lung Cancer | RECRUITING | NCT05632809 |
| enzalutamide | DRUG | Phase PHASE1 | Squamous Cell Carcinoma of the Head and Neck (SCCHN) | TERMINATED | NCT04052204 |
| talazoparib | DRUG | Phase PHASE1 | Squamous Cell Carcinoma of the Head and Neck (SCCHN) | TERMINATED | NCT04052204 |
| avelumab | DRUG | Phase PHASE1 | Squamous Cell Carcinoma of the Head and Neck (SCCHN) | TERMINATED | NCT04052204 |
| Oxycodone IR | DRUG | Phase PHASE1 | Moderate to Severe Chronic Pain | TERMINATED | NCT03802227 |
| cabozantinib | DRUG | Phase PHASE3 | Renal Cell Carcinoma | TERMINATED | NCT03729245 |
| sunitinib | DRUG | Phase PHASE3 | Renal Cell Carcinoma | TERMINATED | NCT03729245 |
| Nivolumab | BIOLOGICAL | Phase PHASE1 | Metastatic Melanoma | WITHDRAWN | NCT04955262 |
| LY3471851 | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT05565729 |
| Bempegaldesleukin | DRUG | Phase PHASE2 | Metastatic Head and Neck Cancer | TERMINATED | NCT04969861 |
| VB10.NEO | BIOLOGICAL | Phase PHASE1 | Locally Advanced or Metastatic Solid Tumours | COMPLETED | NCT03548467 |
| nivolumab | BIOLOGICAL | Phase PHASE3 | Renal Cell Carcinoma | TERMINATED | NCT03729245 |
| bempegaldesleukin | BIOLOGICAL | Phase PHASE3 | Renal Cell Carcinoma | TERMINATED | NCT03729245 |
| NKTR-262 | DRUG | Phase PHASE1 | Melanoma | TERMINATED | NCT03435640 |
| Atezolizumab | DRUG | Phase PHASE1 | Non-Small Cell Lung Cancer | TERMINATED | NCT03138889 |
| Pemetrexed | DRUG | Phase PHASE1 | Non-Small Cell Lung Cancer | TERMINATED | NCT03138889 |
| Nab paclitaxel | DRUG | Phase PHASE1 | Non-Small Cell Lung Cancer | TERMINATED | NCT03138889 |
| Carboplatin | DRUG | Phase PHASE1 | Non-Small Cell Lung Cancer | TERMINATED | NCT03138889 |
| Cisplatin | DRUG | Phase PHASE1 | Non-Small Cell Lung Cancer | TERMINATED | NCT03138889 |
| Pembrolizumab | DRUG | Phase PHASE2 | Metastatic Head and Neck Cancer | TERMINATED | NCT04969861 |
| Dose Expansion Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab | DRUG | Phase PHASE1 | Melanoma | COMPLETED | NCT02983045 |
| Schedule Finding Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab | DRUG | Phase PHASE1 | Melanoma | COMPLETED | NCT02983045 |
| Dose Expansion Doublet: Combination of NKTR-214 + nivolumab | DRUG | Phase PHASE1 | Melanoma | COMPLETED | NCT02983045 |
| Dose Escalation Doublet: Combination of NKTR-214 + nivolumab | DRUG | Phase PHASE1 | Melanoma | COMPLETED | NCT02983045 |
| Nab-paclitaxel | DRUG | Phase PHASE3 | Metastasis | COMPLETED | NCT02915744 |
| Docetaxel | DRUG | Phase PHASE3 | Metastasis | COMPLETED | NCT02915744 |
| Paclitaxel | DRUG | Phase PHASE1 | Non-Small Cell Lung Cancer | TERMINATED | NCT03138889 |
| Gemcitabine | DRUG | Phase PHASE3 | Metastasis | COMPLETED | NCT02915744 |
| Vinorelbine | DRUG | Phase PHASE3 | Metastasis | COMPLETED | NCT02915744 |
| Ixabepilone | DRUG | Phase PHASE3 | Metastasis | COMPLETED | NCT02915744 |
| Eribulin | DRUG | Phase PHASE3 | Metastasis | COMPLETED | NCT02915744 |
| NKTR-214 | DRUG | Phase PHASE2 | Head and Neck Cancer | TERMINATED | NCT04936841 |
| Placebo to match NKTR-181 BID tablets | DRUG | Phase PHASE3 | Low Back Pain | COMPLETED | NCT02362672 |
| NKTR-181 BID tablets | DRUG | Phase PHASE3 | Low Back Pain | COMPLETED | NCT02367820 |
| 50 mg/m2 NKTR 102 | DRUG | Phase PHASE1 | Advanced or Metastatic Solid Tumors in Patients With Hepatic Impairment | COMPLETED | NCT01991678 |
| 120 mg/m2 NKTR 102 | DRUG | Phase PHASE1 | Advanced or Metastatic Solid Tumors in Patients With Hepatic Impairment | COMPLETED | NCT01991678 |
| 145 mg/m2 NKTR 102 | DRUG | Phase PHASE1 | Advanced or Metastatic Solid Tumors in Patients With Hepatic Impairment | COMPLETED | NCT01991678 |
| Pharmacological Study | OTHER | Phase PHASE2 | Recurrent Small Cell Lung Carcinoma | COMPLETED | NCT01876446 |
| Pegylated Irinotecan | DRUG | Phase PHASE2 | Stage IV Non-small Cell Lung Cancer (NSCLC) | COMPLETED | NCT02312622 |
| Laboratory Biomarker Analysis | OTHER | Phase PHASE2 | Recurrent Small Cell Lung Carcinoma | COMPLETED | NCT01876446 |
| Aerosolized Placebo | DRUG | Phase PHASE3 | Pneumonia, Bacterial | COMPLETED | NCT01799993 |
| Amikacin Inhalation Solution (BAY41-6551) | DRUG | Phase PHASE3 | Pneumonia, Bacterial | COMPLETED | NCT01799993 |
| Etirinotecan pegol | DRUG | Phase PHASE2 | Anaplastic Astrocytomas | COMPLETED | NCT01663012 |
| NKTR-181 | DRUG | Phase PHASE1 | Moderate to Severe Chronic Pain | TERMINATED | NCT03802227 |
| Treatment of Physician's Choice (TPC) | DRUG | Phase PHASE3 | Locally Recurrent Breast Cancer | COMPLETED | NCT01492101 |
| NKTR-102 50 mg/m2 | DRUG | Phase PHASE2 | Malignant Solid Tumor | COMPLETED | NCT01457118 |
| NKTR-102 95 mg/m2 | DRUG | Phase PHASE2 | Malignant Solid Tumor | COMPLETED | NCT01457118 |
| NKTR-102 120 mg/m2 | DRUG | Phase PHASE2 | Malignant Solid Tumor | COMPLETED | NCT01457118 |
| NKTR-102 145 mg/m2 | DRUG | Phase PHASE2 | Malignant Solid Tumor | COMPLETED | NCT01457118 |
| Amikacin inhalation solution (BAY41-6551) | DRUG | Phase PHASE2 | Pneumonia | COMPLETED | NCT01021436 |
| Placebo | DRUG | Phase PHASE2 | Alopecia Areata | ACTIVE_NOT_RECRUITING | NCT06340360 |
| Amikacin (BAY41-6551) | DRUG | Phase PHASE2 | Pneumonia | COMPLETED | NCT01004445 |
| irinotecan | DRUG | Phase PHASE2 | Colorectal Cancer | COMPLETED | NCT00856375 |
| NKTR-102 q21d | DRUG | Phase PHASE2 | Tumor | COMPLETED | NCT00806156 |
| NKTR-102 q14d | DRUG | Phase PHASE2 | Tumor | COMPLETED | NCT00806156 |
| NKTR-102 | DRUG | Phase PHASE3 | Metastasis | COMPLETED | NCT02915744 |
| NKTR-118 | DRUG | Phase PHASE2 | Opioid Induced Constipation (OIC) | COMPLETED | NCT00600119 |
| placebo | DRUG | Phase PHASE2 | Opioid Induced Constipation (OIC) | COMPLETED | NCT00600119 |
| Cetuximab | DRUG | Phase PHASE1 | Head and Neck Squamous Cell Carcinoma | COMPLETED | NCT04616196 |
| NKTR-102 125 mg/m2 | DRUG | Phase PHASE2 | Tumor | COMPLETED | NCT00598975 |
| NKTR-102 100 mg/m2 | DRUG | Phase PHASE2 | Tumor | COMPLETED | NCT00598975 |
| aerosolized vancomycin or gentamicin | DRUG | Phase PHASE2 | Ventilator Associated Pneumonia | COMPLETED | NCT00396578 |
| Dronabinol MDI | DRUG | Phase PHASE2 | Migraine With Aura | COMPLETED | NCT00123201 |
Total products: 322